Pediatrics

MD IQ

Feature

Humira biosimilars: Five things to know

The launch of eight adalimumab biosimilars so far in 2023 ended Humira’s 20-year monopoly, but it’s not clear yet if these discounted drugs will...

Commentary

Goodbye, finger sticks; hello, CGMs

It’s easy to determine whether blood sugar is going up or down and the proportion of time the patient spends in or out of the target glucose range...

Pages